Axitinib: Newly Approved for Renal Cell Carcinoma
Timothy Tyler, PharmD, FCSHP
From Desert Regional Medical Center–Comprehensive Cancer Center, Palm Springs, California
Timothy Tyler has served on speakers bureaus for Bristol-Myers Squibb, Janssen, and Eisai.
Correspondence to: Timothy Tyler, PharmD, FCSHP, Desert Regional Medical Center–Comprehensive Cancer Center, 1180 North Indian Canyon Drive, E-218 Pharmacy, Palm Springs, CA 92262. E-mail: Timothy.Tyler@tenethealth.com
J Adv Pract Oncol 2012;3:333–335 |
DOI: 10.6004/jadpro.2012.3.5.7 |
© 2012 Harborside Press®
Data presented at the June 2012 American Society of Clinical Oncology (ASCO) annual meeting reaffirmed the use of axitinib (Inlyta), a potent and selective second-generation inhibitor of vascular endothelial growth factor receptors, for second-line treatment of metastatic renal cell carcinoma (mRCC). Viable treatment options have rapidly progressed from literally almost nothing in the way of effective chemotherapy or targeted therapies less than a decade ago to having to choose from seven new US Food and Drug Administration (FDA)-approved therapies today. The addition of yet another therapy can make it challenging for oncology advanced practitioners (APs) to stay current with respect to the many developments in renal cancer. This article will seek to provide APs with some insight into this most recent drug approval...
The text above is an extract from the article.
For access to the full length article, please sign in